Comparison of clinical effects of rifampicin and rifapentine in the treatment of elderly patients with pulmonary tuberculosis

Wang Lijie; Zhou Guangnao; He Meiyan

doi:10.3760/j.issn.1673-4777.2024.11.010

Abstract：Objective To compare the clinical effect of rifampicin and rifapentine in the treatment of elderly patients with pulmonary tuberculosis.Methods The clinical data of 218 elderly patients with pulmonary tuberculosis admitted to the Department of Tuberculosis,Lishui Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University from January 2020 to December 2022 were retrospectively collected and analyzed.Patients were divided into rifampicin group(109 cases)and rifapentine group(109 cases)according to different drugs.Both groups received conventional anti-tuberculosis treatment.The patients in the rifampicin group were treated with rifampicin on the basis of conventional treatment,and the patients in the rifapentine group were treated with rifapentine on the basis of conventional treatment.All patients were treated for 6 to 12 months.The clinical baseline data,adverse reactions,medication compliance and efficacy were compared between the two groups.Results There were no significant differences in clinical baseline data between the two groups(all P＞0.05).The incidence of adverse reactions in rifampicin group was higher than that in rifapentine group[17.4％(19/109)vs 8.2％(9/109)](x2=4.098,P=0.043).The Morisky medication adherence scale score of the rifampicin group was higher than that of the rifapentine group(P＜0.05).The success rate of rifampicin group was higher than that of rifapentine group(P＞0.05).Conclusion Rifapentine and rifampicin have similar efficacy in the treatment of elderly pulmonary tuberculosis,and with high safety.Rifapentine can be used instead of rifampicin in the selection of anti-tuberculosis regimens for elderly pulmonary tuberculosis.